Literature DB >> 30524909

Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden.

Jan Budczies1,2,3, Anja Seidel1, Petros Christopoulos4,5, Volker Endris2, Matthias Kloor2,6,7, Balázs Győrffy8,9, Barbara Seliger10, Peter Schirmacher2,3, Albrecht Stenzinger2,3, Carsten Denkert1,3.   

Abstract

Harnessing the immune system by checkpoint blockade has greatly expanded the therapeutic options for advanced cancer. Since the efficacy of immunotherapies is influenced by the molecular make-up of the tumor and its crosstalk with the immune system, comprehensive analysis of genetic and immunologic tumor characteristics is essential to gain insight into mechanisms of therapy response and resistance. We investigated the association of immune cell contexture and tumor genetics including tumor mutational burden (TMB), copy number alteration (CNA) load, mutant allele heterogeneity (MATH) and specific mutational signatures (MutSigs) using TCGA data of 5722 tumor samples from 21 cancer types. Among all genetic variables, MutSigs associated with DNA repair deficiency and AID/APOBEC gene activity showed the strongest positive correlations with immune parameters. For smoking-related and UV-light-exposure associated MutSigs a few positive correlations were identified, while MutSig 1 (clock-like process) correlated non-significantly or negatively with the major immune parameters in most cancer types. High TMB was associated with high immune cell infiltrates in some but not all cancer types, in contrast, high CNA load and high MATH were mostly associated with low immune cell infiltrates. While a bi- or multimodal distribution of TMB was observed in colorectal, stomach and endometrial cancer where its levels were associated with POLE/POLD1 mutations and MSI status, TMB was unimodal distributed in the most other cancer types including NSCLC and melanoma. In summary, this study uncovered specific genetic-immunology associations in major cancer types and suggests that mutational signatures should be further investigated as interesting candidates for response prediction beyond TMB.

Entities:  

Keywords:  Immuno-oncology; PD-L1; immune checkpoints; mutational signatures; tumor mutational burden

Year:  2018        PMID: 30524909      PMCID: PMC6279340          DOI: 10.1080/2162402X.2018.1526613

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  47 in total

1.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Authors:  Dung T Le; Jennifer N Durham; Kellie N Smith; Hao Wang; Bjarne R Bartlett; Laveet K Aulakh; Steve Lu; Holly Kemberling; Cara Wilt; Brandon S Luber; Fay Wong; Nilofer S Azad; Agnieszka A Rucki; Dan Laheru; Ross Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Tim F Greten; Austin G Duffy; Kristen K Ciombor; Aleksandra D Eyring; Bao H Lam; Andrew Joe; S Peter Kang; Matthias Holdhoff; Ludmila Danilova; Leslie Cope; Christian Meyer; Shibin Zhou; Richard M Goldberg; Deborah K Armstrong; Katherine M Bever; Amanda N Fader; Janis Taube; Franck Housseau; David Spetzler; Nianqing Xiao; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; James R Eshleman; Bert Vogelstein; Robert A Anders; Luis A Diaz
Journal:  Science       Date:  2017-06-08       Impact factor: 47.728

Review 2.  Cancer immunotherapy using checkpoint blockade.

Authors:  Antoni Ribas; Jedd D Wolchok
Journal:  Science       Date:  2018-03-22       Impact factor: 47.728

3.  Mutant allele tumor heterogeneity (MATH) and head and neck squamous cell carcinoma.

Authors:  James W Rocco
Journal:  Head Neck Pathol       Date:  2015-03-25

4.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

5.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

6.  MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma.

Authors:  Edmund A Mroz; James W Rocco
Journal:  Oral Oncol       Date:  2012-10-15       Impact factor: 5.337

7.  Comprehensive Analysis of Hypermutation in Human Cancer.

Authors:  Brittany B Campbell; Nicholas Light; David Fabrizio; Matthew Zatzman; Fabio Fuligni; Richard de Borja; Scott Davidson; Melissa Edwards; Julia A Elvin; Karl P Hodel; Walter J Zahurancik; Zucai Suo; Tatiana Lipman; Katharina Wimmer; Christian P Kratz; Daniel C Bowers; Theodore W Laetsch; Gavin P Dunn; Tanner M Johanns; Matthew R Grimmer; Ivan V Smirnov; Valérie Larouche; David Samuel; Annika Bronsema; Michael Osborn; Duncan Stearns; Pichai Raman; Kristina A Cole; Phillip B Storm; Michal Yalon; Enrico Opocher; Gary Mason; Gregory A Thomas; Magnus Sabel; Ben George; David S Ziegler; Scott Lindhorst; Vanan Magimairajan Issai; Shlomi Constantini; Helen Toledano; Ronit Elhasid; Roula Farah; Rina Dvir; Peter Dirks; Annie Huang; Melissa A Galati; Jiil Chung; Vijay Ramaswamy; Meredith S Irwin; Melyssa Aronson; Carol Durno; Michael D Taylor; Gideon Rechavi; John M Maris; Eric Bouffet; Cynthia Hawkins; Joseph F Costello; M Stephen Meyn; Zachary F Pursell; David Malkin; Uri Tabori; Adam Shlien
Journal:  Cell       Date:  2017-10-19       Impact factor: 41.582

Review 8.  Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance.

Authors:  Norma Bloy; Pauline Garcia; Céline M Laumont; Jonathan M Pitt; Antonella Sistigu; Gautier Stoll; Takahiro Yamazaki; Eric Bonneil; Aitziber Buqué; Juliette Humeau; Jan W Drijfhout; Guillaume Meurice; Steffen Walter; Jens Fritsche; Toni Weinschenk; Hans-Georg Rammensee; Cornelis Melief; Pierre Thibault; Claude Perreault; Jonathan Pol; Laurence Zitvogel; Laura Senovilla; Guido Kroemer
Journal:  Immunol Rev       Date:  2017-11       Impact factor: 12.988

9.  A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.

Authors:  David L Rimm; Gang Han; Janis M Taube; Eunhee S Yi; Julia A Bridge; Douglas B Flieder; Robert Homer; William W West; Hong Wu; Anja C Roden; Junya Fujimoto; Hui Yu; Robert Anders; Ashley Kowalewski; Christopher Rivard; Jamaal Rehman; Cory Batenchuk; Virginia Burns; Fred R Hirsch; Ignacio I Wistuba
Journal:  JAMA Oncol       Date:  2017-08-01       Impact factor: 31.777

10.  The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells.

Authors:  Nicoletta Casartelli; Florence Guivel-Benhassine; Romain Bouziat; Samantha Brandler; Olivier Schwartz; Arnaud Moris
Journal:  J Exp Med       Date:  2009-12-28       Impact factor: 14.307

View more
  26 in total

1.  B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer.

Authors:  Daniel P Hollern; Nuo Xu; Aatish Thennavan; Cherise Glodowski; Susana Garcia-Recio; Kevin R Mott; Xiaping He; Joseph P Garay; Kelly Carey-Ewend; David Marron; John Ford; Siyao Liu; Sarah C Vick; Miguel Martin; Joel S Parker; Benjamin G Vincent; Jonathan S Serody; Charles M Perou
Journal:  Cell       Date:  2019-11-14       Impact factor: 41.582

2.  Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy.

Authors:  Shiro Takamatsu; Junzo Hamanishi; J B Brown; Ken Yamaguchi; Koji Yamanoi; Kosuke Murakami; Osamu Gotoh; Seiichi Mori; Masaki Mandai; Noriomi Matsumura
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

Review 3.  The immune microenvironment in gastric adenocarcinoma.

Authors:  Yana Zavros; Juanita L Merchant
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-03-14       Impact factor: 73.082

4.  [Research Progress on Heterogeneity of Tumor Mutation Burden in Patients with 
Non-small Cell Lung Cancer].

Authors:  Abdurazik Mihray; Peng Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-04-20

5.  Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors.

Authors:  Dan Sha; Zhaohui Jin; Jan Budczies; Klaus Kluck; Albrecht Stenzinger; Frank A Sinicrope
Journal:  Cancer Discov       Date:  2020-11-02       Impact factor: 38.272

Review 6.  The Importance of the Autopsy in Medicine: Perspectives of Pathology Colleagues.

Authors:  Louis Maximilian Buja; Rolf F Barth; Gerhard R Krueger; Sergey V Brodsky; Robert L Hunter
Journal:  Acad Pathol       Date:  2019-03-10

Review 7.  The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.

Authors:  Denis L Jardim; Aaron Goodman; Debora de Melo Gagliato; Razelle Kurzrock
Journal:  Cancer Cell       Date:  2020-10-29       Impact factor: 31.743

8.  Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant POLE/POLD1 Colon Cancer.

Authors:  Ajaratu Keshinro; Chad Vanderbilt; Jin K Kim; Canan Firat; Chin-Tung Chen; Rona Yaeger; Karuna Ganesh; Neil H Segal; Mithat Gonen; Jinru Shia; Zsofia Stadler; Martin R Weiser
Journal:  JCO Precis Oncol       Date:  2021-05-12

9.  Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer.

Authors:  Zhihao Lu; Huan Chen; Shuang Li; Jifang Gong; Jian Li; Jianling Zou; Lihong Wu; Jianing Yu; Wenbo Han; Huaibo Sun; Xi Jiao; Xiaotian Zhang; Zhi Peng; Ming Lu; Zhenghang Wang; Henghui Zhang; Lin Shen
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751

10.  Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma.

Authors:  Laia Bassaganyas; Roser Pinyol; Roger Esteban-Fabró; Laura Torrens; Sara Torrecilla; Catherine E Willoughby; Sebastià Franch-Expósito; Maria Vila-Casadesús; Itziar Salaverria; Robert Montal; Vincenzo Mazzaferro; Jordi Camps; Daniela Sia; Josep M Llovet
Journal:  Clin Cancer Res       Date:  2020-09-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.